The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate

British Journal of Dermatology

Volumn 140, Issue 6, 1999, Pages 1115-1121

  Van Der Meer, J B ^d   Glazenburg, E J ^a   Mulder, P G H ^b   Eggink, H F ^c   Coenraads, P J ^d  

^a GLAXOSMITHKLINE   (United States)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c Public Health Service of Northern Friesland   (Netherlands)

^d NONE

Author keywords

Atopic dermatitis; Fluticasone propionate; Intermittent dosing; Local and systemic activity; Maintenance treatment; Placebo

Indexed keywords

FLUTICASONE PROPIONATE; PLACEBO;

ADOLESCENT; ADULT; ARTICLE; ATOPIC DERMATITIS; BACTERIAL INFECTION; CLINICAL TRIAL; CORTICOSTEROID THERAPY; EYELID EDEMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PRURITUS; RECURRENT DISEASE; RELAPSE; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0033016393     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1999.02893.x     Document Type: Article

References (28)

1. 1 McGregor JM, Rustin MHA. Eczema. In: Handbook of Current Diagnosis and Treatment (Pounder R, Hamilton M, eds). Edinburgh: Churchill Livingstone, 1995; 122-3.
2. 2 Ring J, Brockow K, Abeck D. The therapeutic concept of 'patient management' in atopic eczema. Allergy 1996; 51: 206-15.
3. 3 Przybilla B, Eberlein-König B, Rueff F. Practical management of atopic eczema. Lancet 1994; 343: 1342-6.
4. 4 Niedner R, Schöpf E. Clinical efficacy of topical glucocorticoid preparations and other types of dermatics in inflammatory diseases, particularly in atopic dermatitis. Curr Probl Dermatol 1993; 21: 157-69.
5. 5 Degreef H, Dooms-Goossens A. The new corticosteroids: are they effective and safe? Dermatol Clin 1993; 11: 155-60.
6. 6 Katz HI, Prawer SE, Medansky RS et al. Intermittent corticosteroid maintenance treatment of psoriasis: a double blind multicenter trial of augmented betamethasone dipropionate in a pulse dose treatment regimen. Dermatologica 1991; 183: 269-74.
7. 7 Möller H, Svartholm H, Dahl G. Intermittent maintenance therapy in chronic hand eczema with clobetasol propionate and flupredniden acetate. Curr Med Res Opin 1983; 8: 640-4.
8. 8 Korting HC. Dermatotherapie: ein Leitfaden. Berlin: Springer-Verlag. 1995.
9. 9 van der Meer JB. How safe (dangerous) are topical corticosteroids in long-term therapies in dermatology? Guidelines for topical therapy with corticosteroids. Ned Tijdschr Dermatol Venereol 1997; 7: 48-51.
10. 10 Högger P, Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids 1994; 59: 597-602.
11. 11 Chu AC, Munn S. Fluticasone propionate in the treatment of inflammatory dermatoses. Br J Clin Pract 1995; 49: 131-3.
12. 12 Johnson M. Fluticasone propionate: safety profile. Cutis 1996; 57: 10-12.
13. 13 Harding SM. The human pharmacology of fluticasone propionate. Respir Med 1990; 84 (Suppl. A): 25-9.
14. 14 Dollery C. Fluticasone propionate. In: Therapeutic Drugs, Supplement 2. Edinburgh: Churchill Livingstone, 1994; S102-5.
15. 15 Holiday SM, Faulds D, Sorkin EM. Inhaled fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in asthma. Drugs 1994; 47: 318-31.
16. 16 Piacquadio DJ. Topical corticosteroids in clinical practice: focus on fluticasone propionate. Cutis 1996; 57: 4-9.
17. 17 Bleehen SS, Chu AC, Hamann I et al. Fluticasone propionate 0.05% cream in the treatment of atopic eczema: a multicentre study comparing once-daily treatment and once-daily vehicle cream application versus twice-daily treatment. Br J Dermatol 1995; 133: 592-7.
18. 18 Tharp MD. A comparison of twice-daily and once-daily administration of fluticasone propionate cream, 0.05%, in the treatment of eczema. Cutis 1996; 57: 19-26.
19. 19 Spencer CM, Wiseman LR. Topical fluticasone propionate. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. BioDrugs 1947; 7: 318-34.
20. 20 Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980; Suppl. 92: 44-7.
21. 21 Consensus report of the European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD index. Dermatology 1993; 186: 23-31.
22. 22 Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172: 902-8.
23. 23 Lebwohl M. Efficacy and safety of fluticasone propionate ointment, 0.005%, in the treatment of eczema. Cutis 1996; 57: 62-8.
24. 24 Delescluse J, van der Endt JD. A comparison of the safety, tolerabilily, and efficacy of fluticasone propionate ointment, 0.005%, and betamethasone-17,21-dipropionate ointment. 0.05%, in the treatment of eczema. Cutis 1996; 57: 32-8.
25. 25 Juhlin L. Comparison of fluticasone propionate cream, 0.05%, and hydrocortisone-l7-butyrate cream, 0.1%, in the treatment of eczema. Cutis 1996; 57: 51-6.
26. 26 Young MMR, Sohail N, Harding SM. A comparison of the systemic absorption of fluticasone propionate and betamethasone valerate after topical application of cream formulations. Br J Dermatol 1994; 131 (Suppl. 44): 35-6.
27. 27 Svartholm H, Larsson L, Frederiksen B. Intermittent topical treatment of psoriasis with clobetasol propionate ('Dermovate'). Curr Med Res Opin 1982; 8: 154-7.
28. 28 Katz HI, Hien NT, Prawer SE et al. Betamethasone dipropionate in optimised vehicle: intermittent pulse dosing for extended maintenance treatment of psoriasis. Arch Dermatol 1987; 123: 1308-11.